Clinical

B. Besse, S. Almokadem, C. Tsao, H. Ding, D.T. Chico, J.C. I. Chico, J.C. Soria, C.P. Belani. Volociximab in Combination with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). ESMO 2009, poster presentation.

S Yazji, R Bukowski, V Kondagunta, S Bai, R Figlin. Final Results from Cohort 1 of a Phase 2 Study of Volociximab, an Anti-a5B1 Integrin Monoclonal Antibody, in Patients with Metastatic Renal Cell Carcinoma (mRCC). ASCO 2007, poster presentation.

TRJ Evans, RK Ramanathan, S Yazji, R Glynne-Jones, A Anthoney, J Berlin, JW Valle. Final Results from Cohort 1 of a Phase 2 Study of Volociximab, an Anti-a5B1 Integrin Antibody, in Combination with Gemcitabine (Gem) in Patients with Metastatic Pancreatic Cancer (MPC). ASCO 2007, poster presentation.

LD Cranmer, AY Bedikian, A Ribas, S O'Day, A Forero-Torres, S Yazji, JM Kirkwood. Phase II Study of Volociximab (M200), an α5β1 Anti-Integrin Antibody in Metastatic Melanoma, ASCO 2006, poster presentation.

RA Figlin, GV Kondagunta, S Yazji, RJ Motzer, RM Bukowski. Phase II Study of Volociximab (M200), an α5ß1 Anti-integrin Antibody in Refractory Metastatic Clear Cell Renal Cell Cancer (RCC). ASCO 2006, poster presentation.

JW Valle, RK Ramanathan, R Glynne-Jones, A Anthoney, J Berlin, S Yazji, T Evans. Phase II Study of Volociximab (M200), α5ß1 an Anti-integrin Antibody in Metastatic Adenocarcinoma of the Pancreas (MPC). ASCO 2006, poster presentation.